Efficacy and safety of higher-dose intravenous ciprofloxacin in severe hospital-acquired infections
Article Abstract:
The fluoroquinolone antibiotic ciprofloxacin was used to treat nosocomial, or hospital-acquired, life-threatening infections in 54 patients, most of whom had pneumonia. Eighty-eight infective bacteria, most commonly Pseudomonas aeruginosa, Serratia marcescens, Staphylococcus aureus, and Enterobacter were isolated from 50 of the patients. Infective bacteria could not be identified in three patients with pneumonia and one patient with a urinary tract infection. Ciprofloxacin was given parenterally, or directly into the circulation, in 44 patients, orally in four patients, and by both routes in six patients. Drug treatment cured 21 patients, improved infections in 23 patients, had no effect in two patients, and could not be evaluated in eight patients. Ciprofloxacin had adverse effects in twelve patients, including disorders in liver function, convulsions, and inflammation of the skin. The results demonstrate that high doses of ciprofloxacin given parenterally are effective in the treatment of severe infections in intensive care patients. (Consumer Summary produced by Reliance Medical Information, Inc.)
Publication Name: American Journal of Medicine
Subject: Health care industry
ISSN: 0002-9343
Year: 1989
User Contributions:
Comment about this article or add new information about this topic:
Comparison of ciprofloxacin with ampicillin in acute infectious exacerbations of chronic bronchitis
Article Abstract:
The effects of two antibiotics, ciprofloxacin and ampicillin were compared in 22 patients with bacterial infections associated with asthma and/or bronchitis (inflammation of the bronchi which lead from the upper respiratory tract to the lungs). Ciprofloxacin was given in doses of 750 milligrams twice daily, whereas ampicillin was given in doses of 500 milligrams four times daily; both antibiotics were administered for 14 days. The results demonstrate that ampicillin and ciprofloxacin improved the bacterial infections. Thus, the quinolone antibiotic ciprofloxacin is as effective as ampicillin in the treatment of bacterial infections associated with chronic or long-term bronchial disease. Ciprofloxacin appears to be superior in eliminating infective bacteria from the sputum, the fluid substance produced upon coughing or clearing the throat. (Consumer Summary produced by Reliance Medical Information, Inc.)
Publication Name: American Journal of Medicine
Subject: Health care industry
ISSN: 0002-9343
Year: 1989
User Contributions:
Comment about this article or add new information about this topic: